Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer

Ioannis Hatzipetros, Peter Gocze, T. Kőszegi, Akos Jaray, L. Szereday, B. Polgár, Nelli Farkas, Balint Farkas

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective. Recently, 14-3-3 zeta protein was identified as a potential serum biomarker of epithelial ovarian cancer (EOC). The goal of this study was to investigate the clinical potential of 14-3-3 zeta protein for monitoring EOC progression compared with CA-125 and HE4. Design. Prospective follow-up study. Setting. University of Pecs Medical Center Department of Obstetrics and Gynecology/Oncology (Pecs, Hungary). Population. Thirteen EOC patients with advanced stage (FIGO IIb-IIIc) epithelial ovarian cancer that underwent radical surgery and received six consecutive cycles of first line chemotherapy (paclitaxel, carboplatin) in 21-day intervals. Methods. Pre- and post-chemotherapy computed tomography (CT) scans were performed. Serum levels of CA-125, HE4, and 14-3-3 zeta protein were detected by enzyme-linked immunosorbent assay (ELISA) and quantitative electrochemiluminescence assay (ECLIA). Main outcome measures. Serum levels of CA-125, HE4, and 14-3-3 zeta protein, as well as lesion size according to pre- and post-chemotherapy CT scans. Results: Serum levels of CA-125 and HE4 were found to significantly decrease following chemotherapy, and this was consistent with the decrease in lesion size detected post-chemotherapy. In contrast, 14-3-3 zeta protein levels did not significantly differ in healthy postmenopausal patients versus EOC patients. Conclusions: Determination of CA-125 and HE4 serum levels for the determination of the risk of ovarian malignancy algorithm (ROMA) represents a useful tool for the prediction of chemotherapy efficacy for EOC patients. However, levels of 14-3-3 zeta protein were not found to vary significantly as a consequence of treatment. Therefore we question if 14-3-3 zeta protein is a reliable biomarker, which correlates with the clinical behavior of EOC.

Original languageEnglish
Article number79
JournalJournal of Ovarian Research
Volume6
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

14-3-3 Proteins
Biomarkers
Drug Therapy
Serum
Tomography
Hospital Obstetrics and Gynecology Department
Ovarian epithelial cancer
Hungary
Carboplatin
Paclitaxel
Gynecology
Enzyme-Linked Immunosorbent Assay
Outcome Assessment (Health Care)

Keywords

  • 14-3-3 Zeta protein
  • CA-125
  • Chemotherapy
  • Epithelial ovarian cancer
  • HE-4
  • ROMA

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer. / Hatzipetros, Ioannis; Gocze, Peter; Kőszegi, T.; Jaray, Akos; Szereday, L.; Polgár, B.; Farkas, Nelli; Farkas, Balint.

In: Journal of Ovarian Research, Vol. 6, No. 1, 79, 2013.

Research output: Contribution to journalArticle

@article{0578a16baa55475f8ff5a576f188f8bf,
title = "Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer",
abstract = "Objective. Recently, 14-3-3 zeta protein was identified as a potential serum biomarker of epithelial ovarian cancer (EOC). The goal of this study was to investigate the clinical potential of 14-3-3 zeta protein for monitoring EOC progression compared with CA-125 and HE4. Design. Prospective follow-up study. Setting. University of Pecs Medical Center Department of Obstetrics and Gynecology/Oncology (Pecs, Hungary). Population. Thirteen EOC patients with advanced stage (FIGO IIb-IIIc) epithelial ovarian cancer that underwent radical surgery and received six consecutive cycles of first line chemotherapy (paclitaxel, carboplatin) in 21-day intervals. Methods. Pre- and post-chemotherapy computed tomography (CT) scans were performed. Serum levels of CA-125, HE4, and 14-3-3 zeta protein were detected by enzyme-linked immunosorbent assay (ELISA) and quantitative electrochemiluminescence assay (ECLIA). Main outcome measures. Serum levels of CA-125, HE4, and 14-3-3 zeta protein, as well as lesion size according to pre- and post-chemotherapy CT scans. Results: Serum levels of CA-125 and HE4 were found to significantly decrease following chemotherapy, and this was consistent with the decrease in lesion size detected post-chemotherapy. In contrast, 14-3-3 zeta protein levels did not significantly differ in healthy postmenopausal patients versus EOC patients. Conclusions: Determination of CA-125 and HE4 serum levels for the determination of the risk of ovarian malignancy algorithm (ROMA) represents a useful tool for the prediction of chemotherapy efficacy for EOC patients. However, levels of 14-3-3 zeta protein were not found to vary significantly as a consequence of treatment. Therefore we question if 14-3-3 zeta protein is a reliable biomarker, which correlates with the clinical behavior of EOC.",
keywords = "14-3-3 Zeta protein, CA-125, Chemotherapy, Epithelial ovarian cancer, HE-4, ROMA",
author = "Ioannis Hatzipetros and Peter Gocze and T. Kőszegi and Akos Jaray and L. Szereday and B. Polg{\'a}r and Nelli Farkas and Balint Farkas",
year = "2013",
doi = "10.1186/1757-2215-6-79",
language = "English",
volume = "6",
journal = "Journal of Ovarian Research",
issn = "1757-2215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer

AU - Hatzipetros, Ioannis

AU - Gocze, Peter

AU - Kőszegi, T.

AU - Jaray, Akos

AU - Szereday, L.

AU - Polgár, B.

AU - Farkas, Nelli

AU - Farkas, Balint

PY - 2013

Y1 - 2013

N2 - Objective. Recently, 14-3-3 zeta protein was identified as a potential serum biomarker of epithelial ovarian cancer (EOC). The goal of this study was to investigate the clinical potential of 14-3-3 zeta protein for monitoring EOC progression compared with CA-125 and HE4. Design. Prospective follow-up study. Setting. University of Pecs Medical Center Department of Obstetrics and Gynecology/Oncology (Pecs, Hungary). Population. Thirteen EOC patients with advanced stage (FIGO IIb-IIIc) epithelial ovarian cancer that underwent radical surgery and received six consecutive cycles of first line chemotherapy (paclitaxel, carboplatin) in 21-day intervals. Methods. Pre- and post-chemotherapy computed tomography (CT) scans were performed. Serum levels of CA-125, HE4, and 14-3-3 zeta protein were detected by enzyme-linked immunosorbent assay (ELISA) and quantitative electrochemiluminescence assay (ECLIA). Main outcome measures. Serum levels of CA-125, HE4, and 14-3-3 zeta protein, as well as lesion size according to pre- and post-chemotherapy CT scans. Results: Serum levels of CA-125 and HE4 were found to significantly decrease following chemotherapy, and this was consistent with the decrease in lesion size detected post-chemotherapy. In contrast, 14-3-3 zeta protein levels did not significantly differ in healthy postmenopausal patients versus EOC patients. Conclusions: Determination of CA-125 and HE4 serum levels for the determination of the risk of ovarian malignancy algorithm (ROMA) represents a useful tool for the prediction of chemotherapy efficacy for EOC patients. However, levels of 14-3-3 zeta protein were not found to vary significantly as a consequence of treatment. Therefore we question if 14-3-3 zeta protein is a reliable biomarker, which correlates with the clinical behavior of EOC.

AB - Objective. Recently, 14-3-3 zeta protein was identified as a potential serum biomarker of epithelial ovarian cancer (EOC). The goal of this study was to investigate the clinical potential of 14-3-3 zeta protein for monitoring EOC progression compared with CA-125 and HE4. Design. Prospective follow-up study. Setting. University of Pecs Medical Center Department of Obstetrics and Gynecology/Oncology (Pecs, Hungary). Population. Thirteen EOC patients with advanced stage (FIGO IIb-IIIc) epithelial ovarian cancer that underwent radical surgery and received six consecutive cycles of first line chemotherapy (paclitaxel, carboplatin) in 21-day intervals. Methods. Pre- and post-chemotherapy computed tomography (CT) scans were performed. Serum levels of CA-125, HE4, and 14-3-3 zeta protein were detected by enzyme-linked immunosorbent assay (ELISA) and quantitative electrochemiluminescence assay (ECLIA). Main outcome measures. Serum levels of CA-125, HE4, and 14-3-3 zeta protein, as well as lesion size according to pre- and post-chemotherapy CT scans. Results: Serum levels of CA-125 and HE4 were found to significantly decrease following chemotherapy, and this was consistent with the decrease in lesion size detected post-chemotherapy. In contrast, 14-3-3 zeta protein levels did not significantly differ in healthy postmenopausal patients versus EOC patients. Conclusions: Determination of CA-125 and HE4 serum levels for the determination of the risk of ovarian malignancy algorithm (ROMA) represents a useful tool for the prediction of chemotherapy efficacy for EOC patients. However, levels of 14-3-3 zeta protein were not found to vary significantly as a consequence of treatment. Therefore we question if 14-3-3 zeta protein is a reliable biomarker, which correlates with the clinical behavior of EOC.

KW - 14-3-3 Zeta protein

KW - CA-125

KW - Chemotherapy

KW - Epithelial ovarian cancer

KW - HE-4

KW - ROMA

UR - http://www.scopus.com/inward/record.url?scp=84887541154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887541154&partnerID=8YFLogxK

U2 - 10.1186/1757-2215-6-79

DO - 10.1186/1757-2215-6-79

M3 - Article

VL - 6

JO - Journal of Ovarian Research

JF - Journal of Ovarian Research

SN - 1757-2215

IS - 1

M1 - 79

ER -